The LTI-01-2001 phase 2a trial of intrapleural LTI-01 in patients with infected, non-draining pleural effusions Authors: Carla R Lamb, Jason Akulian, Ali Musani, Samira Shojaee, Alexander Chen, Jonathan Kurman, Pushan Jani, Michal Senitko, Danish Ahmad, Momen Wahidi, Sikandar Ansari, Muhanned Abu-Hijleh, Kevin C Ma, Jonathan Puchalski, Lonny Yarmus, Fayez Kheir, Fabien Maldonado, George Cheng, Christian Alvarado, Singh P Karan, Brian Windsor, Najib M Rahman, Steven Shoemaker, Steven Idell Published: 2026 ABSTRACT AbstractBackgroundSingle chain urokinase (LTI-01) intrapleural enzymatic therapy (IET) was safe and promising in a phase 1 clinical trial to overcome failed drainage in patients with pleural infection. The LTI-01-2001 phase 2a trial was a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study in hospitalized subjects with infected, non-draining pleural effusions.MethodsLTI-01, in doses of 400,000, 800,000 or 1,200,000 Units, or placebo was administered intrapleurally once daily for up to 3 days. The primary efficacy endpoint was incidence of treatment failure within 7 days of starting study medication. Treatment failure was defined as requiring alternative pleural therapy irrespective of subsequent treatment. Pleural opacification was a secondary endpoint and was assessed by CT imaging of the change in opacified area expressed as a percentage of the ipsilateral hemithorax (relative change) or absolute change in pleural opacification volume expressed in liters.Results40/43 enrolled patients received LTI-01 or placebo due to constraints of the COVID-19 pandemic. There was no significant difference in incidence of treatment failure between the LTI-01 and placebo groups (OR 1.04, 95% CI 0.24,4.44, P = 0.96) while two predetermined sensitivity analyses demonstrated trends of improved efficacy in the 400,000 U group (P = 0.052 and 0.147). The absolute (Liters; L) and relative change from baseline in opacity volume were − 0.28 L (p=0.035) and − 55.8% (P = 0.064) versus placebo in the 800,000 U group, with significant reduction in absolute opacification found in the 400,000 and all LTI-01-treated groups combined (P < 0.03, respectively). There were no safety signals of concern, nor were there any episodes of intrapleural or pulmonary bleeding in LTI-01-treated patients.ConclusionsNo statistically significant difference in the incidence of treatment failure was seen, potentially related to low recruitment. Trends towards efficacy were observed in predetermined sensitivity analyses at the 400,000 U dose of intrapleural LTI-01. Pleural opacification appeared most improved by the 800,000 U intrapleural LTI-01. A larger phase 2b trial is required to confirm these results or determine the efficacy of LTI-01 in patients with organizing, nondraining, infected pleural effusions.Trial registrationClinicalTrials.gov NCT04159831. Registration date: November 12, 2019.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12931-026-03782-4.Keywords: Empyema, Single chain urokinase plasminogen activator, Fibrinolysis, Intrapleural enzymatic therapy, Complicated parapneumonic pleural effusions, Nondraining pleural effusions, Plasminogen activator inhibitor-1 Background Intrapleural organization with fibrinous loculations can impair pleural drainage and negatively impact outcomes of infectious pleural diseases such as empyema or complicated parapneumonic pleural effusions (CPE) [1]. For over seventy-five years, intrapleural enzymatic therapy (IET) has been used as an adjunct to antibiotics and chest tube drainage to clear loculated collections of inflammatory pleural fluid, expedite drainage and improve clinical outcomes [1, 2].IET is now often used prior to surgical referral or in patients who are not surgical candidates, but treatment failure can occur in up to 25% of patients and IET dosing is empiric [3, 4]. At present, the combination of tPA and DNase is most common form of IET, based on efficacy demonstrated in the MIST2 clinical trial [5]. Single chain urokinase (scuPA) is a proenzyme that exhibits Plasminogen Activator Inhibitor-1 (PAI-1) resistant properties that contribute to its ability to effectively and safely clear fibrinous pleural collections in rabbit models of pleural loculation and empyema [6, 7]. With the support of a Science Moving TowArds Research Translation and Therapy (SMARTT) contract (HHSN268201100014C) from the NHLBI, the expression of scuPA in Chinese Hamster Ovarian (CHO) cells was improved and toxicology studies were done to support approval of a clinical trial testing program that was initiated by Lung Therapeutics Incorporated (LTI), which continued to optimize expression and stability of the scuPA drug product, called LTI-01. LTI-01 demonstrated good bioavailability, safety with once daily dosing and no bleeding in a phase 1 dose-ranging trial conducted in patients with empyema/CPE and failed pleural drainage in Australia [8]. To our knowledge, this was the first dose ranging trial of IET in the field and hints of efficacy including reduction of pleural opacification were observed. Based on strong supporting preclinical and clinical data, we infer that LTI-01 IET can more safely and effectively relieve impaired drainage in patients with empyema/CPE due to increased bioavailability and reduced bleeding risk compared to currently used off-label IET regimens, particularly those including tPA, which is highly susceptible to inactivation by PAI-1. Here, we report the results of the phase 2a trial of intrapleural LTI-01 in patients with empyema/CPE and failed pleural drainage. This was a multicenter, double blind, randomized, placebo-controlled, dose-ranging study in hospitalized subjects with infected, non-draining pleural effusions conducted in the USA from September 2020 to March 2022 (Fig. 1). A range of clinical outcomes, including treatment failure or mortality and pleural opacification change were assessed to enable larger scale clinical trial testing of the ability of intrapleural LTI-01 to expedite drainage of pleural fluids and improve the clinical status of patients with infected, non-draining pleural effusions. A key objective prior to trial initiation was also to identify an effective dose(s) with a favorable benefit risk profile to enable Phase 2b or 3 dosing of LTI-01 administered intrapleurally in patients with infected, non-draining pleural effusions. A. Consort Flow Diagram Methods Sex as a biologic variable Both male and female subjects were included in this study, as shown in Table 1. The findings were anticipated to be relevant to each sex, as pleural infections and complications occur in both. Table 1Subject Demographics and Baseline Characteristics mITT PopulationCategoryLTI-01(400,000 U)N=10n (%)LTI-01(800,000 U) N = 9n (%)LTI-01 (1,200,000 U)N = 10 n (%)LTI-01OverallN=29n (%)Placebo N = 11 n (%)Age (Years) MedianMin/Max58.536/9057.020/7863.034/8758.020/9066.044/72Sex (n, %) MaleFemale6 (60)4 (40)5 (55.6)4 (44.4)6 (60)4 (40)17 (58.6)12 (41.4)8 (72.7)3 (27.3)Race: Asian (%)Black (%)White (%)1 (10)1 (10)8 (80)02 (22.2)6 (66.2)1 (10)2 (20)7 (70)2 (6.9)5 (17.2)21 (72.4)01(9.1)10 (90.9)Weight MedianMin/Max87.734.5/131.768.843.5/101.489.352.1/137.079.334.5/137.078.047.72/113.3RAPID: Low Risk; 0–2(%) Moderate Risk; 3–4High Risk; 5–75 (50)5 (50)04 (44.4)5 (55.6)03 (30)4 (40)3 (30)12 (41.4)14 (48.3)3 (10.3)4 (36.4)6 (54.5)1 (9.1)Legend. One patient in the 800,000 U group was listed as “Other” race. RAPID: Scoring system to predict outcomes after pleural infection (9). mITT: Modified Intent to Treat Subject Demographics and Baseline Characteristics mITT Population Age (Years) Median Min/Max 58.5 36/90 57.0 20/78 63.0 34/87 58.0 20/90 66.0 44/72 Sex (n, %) Male Female 6 (60) 4 (40) 5 (55.6) 4 (44.4) 6 (60) 4 (40) 17 (58.6) 12 (41.4) 8 (72.7) 3 (27.3) Race: Asian (%) Black (%) White (%) 1 (10) 1 (10) 8 (80) 0 2 (22.2) 6 (66.2) 1 (10) 2 (20) 7 (70) 2 (6.9) 5 (17.2) 21 (72.4) 0 1(9.1) 10 (90.9) Weight Median Min/Max 87.7 34.5/131.7 68.8 43.5/101.4 89.3 52.1/137.0 79.3 34.5/137.0 78.0 47.72/113.3 RAPID: Low Risk; 0–2 (%) Moderate Risk; 3–4 High Risk; 5–7 5 (50) 5 (50) 0 4 (44.4) 5 (55.6) 0 3 (30) 4 (40) 3 (30) 12 (41.4) 14 (48.3) 3 (10.3) 4 (36.4) 6 (54.5) 1 (9.1) Legend. One patient in the 800,000 U group was listed as “Other” race. RAPID: Scoring system to predict outcomes after pleural infection (9). mITT: Modified Intent to Treat Study design This was a phase 2a randomized, double-blind, placebo-controlled, multi-center, dose- ranging study conducted in hospitalized subjects at 18 sites in the US with infected, non-draining pleural effusions due to empyema/CPE. The trial was sponsored by Lung Therapeutics, Inc. (LTI) using company resources. The findings from the Phase 1 study supported further clinical development in the LTI-01-2001 and the trial design is illustrated (Fig. 1). Planned trial enrollment and the dosing range are shown in Fig. 1A and the trial flow chart is shown in Fig. 1B. Monitoring for dose limiting toxicity (DLT) was done by the iDMC. LTI held the investigational IND for this trial, which was conducted between September of 2020 and July of 2022 with last update in March of 2023. The ClinicalTrials.gov registration number is NCT04159831. The authors designed or performed the trial, analyzed and archived the data, made the decision to submit the publication and vouch for the accuracy of the data and analyses. The study protocol is included in the Supplement to this article. Patient eligibility, inclusion and exclusion criteria Eligible patients met all of the following inclusion criteria (Please refer to Supplement Study Protocol for details) : (1) Male or female ≥ 18 years of age (2) Clinical presentation compatible with CPE, empyema or other type of pleural infection (3) Pleural fluid requiring drainage as determined by chest ultrasonography, chest radiograph or chest CT which was either purulent, gram stain positive, culture positive, or pH < 7.2, glucose < 60 mg/dL (3.3 mmol/L). All patients had failure to adequately drain pleural fluid at least 3 h after insertion of patent chest tube within the pleural space, as evidenced by 1 or more of the following criteria: 1) > 2 cm depth of fluid by ultrasound, chest radiograph or chest CT 2) < 80% drainage by chest radiograph compared with that obtained prior to chest tube. The sizes of the initial chest tubes used in each patient across treatment groups are shown in Table 5 of the Supplement Additional Tables. Exclusion related criteria included prior therapy with IET, fibrothorax, non-expandable lung preceding the present infectious episode and known malignant pleural effusions. Bleeding related exclusions included full anticoagulation, active bleeding or major trauma within 30 days. A full description of all exclusion criteria is provided in the Trial Protocol in the Supplement. Irrigation with normal saline was not used to facilitate pleural drainage in this trial. Table 5Absolute and Relative Change from Baseline of Pleural Opacity VolumeStatisticsLTI-01(400,000 U)N = 10LTI-01(800,000 U)N = 9LTI-01(1,200,000 U)N = 10LTI-01OverallN = 29PlaceboN = 11Absolute Change from Baseline (L)n109102911Median-0.255-0.280-0.140-0.250-0.100p-value0.0270.0350.3110.026Relative Change from Baseline (%)n109102911Median-33.84-55.83-23.04-31.91-16.05p-value0.0820.0640.4660.070Legend. CI Confidence interval. Differences in LTI-01 treatment groups versus placebo controls are represented Absolute and Relative Change from Baseline of Pleural Opacity Volume Legend. CI Confidence interval. Differences in LTI-01 treatment groups versus placebo controls are represented Randomization, monitoring and outcomes Randomization occurred using an Interactive Response Technology that notified unblinded pharmacy personnel of the dose assignment for specific study patients. Eligible patients were randomized in a 1:1:1:1 ratio to 1 of 4 dosing arms: placebo (intrapleural saline), 400,000 Units (U), 800,000 U or 1,200,000 U of LTI-01 with 25–40 patients per arm planned (100–160 patients total), in a double blinded fashion (investigators and patients, Fig. 1a). After the first 12 patients were randomized, subsequent patients were stratified for randomization based upon RAPID score to assess severity of the illness attributable to pleural infection [9]. The first 12 participants were intentionally not stratified by RAPID score because this initial cohort functioned primarily as a safety lead-in phase for evaluation of the previously unstudied 1,200,000 U dose of LTI-01. At the time of study initiation, additional tolerability and safety data were required before broader enrollment into this higher-dose arm could be justified. Therefore, the first 12 eligible participants were randomized equally across the four treatment arms (placebo, 400,000 U, 800,000 U, and 1,200,000 U) without stratification, and enrollment was paused after completion of this cohort for independent Data Monitoring Committee (iDMC) review. This design ensured that three participants were exposed to each dosing arm, including the novel 1,200,000 U dose, before continuation of the trial, but could skew distribution of more severe cases within the relatively small numbers of remaining cases that were randomized to each group. Following confirmation by the iDMC that no significant tolerability concerns were identified, enrollment resumed using RAPID score stratification (low, medium, and high-risk categories) to ensure balanced allocation of clinical risk across treatment groups for the remainder of the study population. Patients received once-daily doses of study medication (LTI-01 or placebo) administered intrapleurally on Days 1, 2 and 3 (Fig. 1B). Patients were monitored daily until hospital discharge for continued, non-improving pleural infection and inadequate pleural fluid drainage. Patients who required alternative pleural therapy (tPA/DNase or surgical intervention) due to worsening or non-improving infected, non-draining pleural effusion, were considered treatment failures. Treatment failure in patients requiring alternative pleural therapy was defined as meeting protocol-specified criteria for surgical referral irrespective of subsequent treatment. In the event of treatment failure, patients were assessed by chest CT prior to surgery or initiation of alternative therapy; use of an alternative agent or surgical intervention. Treatment failures were communicated to the Sponsor Medical Monitor within 24 h of referral to surgery or initiation of additional treatment. Documentation included confirmation of protocol-defined criteria for surgical referral or the rationale for surgical referral in its absence. It should also be noted that the treating clinicians were not restricted from treating subjects according to their own assessments to ensure that subjects were receiving safe and effective therapy in this placebo-controlled trial. Outcome measure definitions derived from meetings involving clinicians with expertise in the field and internal trial design discussions. Primary endpoint The primary efficacy endpoint was the incidence of treatment failure or death within 7 days of starting study medication with treatment failure defined as requiring alternative pleural therapy and meeting protocol-specified criteria for surgical referral irrespective of subsequent treatment. Protocol-specified criteria for surgical referral included: Failure of complete pleural drainage as evidenced by > 2 cm pleural density assessed by chest computerized tomography (CT), chest radiograph or ultrasound. clinical AND evidence of ongoing systemic inflammatory response syndrome (SIRS) or pleural sepsis defined as ≥ 2 of: (1) Body temperature > 38 °C or < 36 °C for at least 2 observations in a 24-hour period (2) Heart rate > 90 beats per minute (BPM) for at least 2 observations in a 24-hour period (3) Respiratory rate > 20 breaths per minute or partial pressure of carbon dioxide in arterial blood (PaCO2) < 32 mmHg (4) White blood cell (WBC) count > 12,000/mm3, < 4,000/mm3 or > 10% bands (5) Systolic blood pressure (SBP) < 100 or SBP drop ≥ 30 mmHg for at least 2 observations in a 24-hour period (6) C-reactive protein (CRP) < 50% reduced from study baseline. Two other prespecified primary analyses were also performed to assess the ability LTI-01 to affect the primary endpoint. The first was an analysis done by an iEAC assessment of treatment failure. The iEAC consisted of two academic interventional pulmonologists from the UK and one thoracic surgeon from Canada. In a second prespecified endpoint analysis, treatment failure was defined as requiring rescue therapy as determined by the treating physician. Secondary endpoints Included absolute and relative change from baseline in pleural opacity volume assessed by chest CT at Day 4 or prior to initiation of alternative pleural therapy in the event of treatment failure. If a patient was considered a treatment failure on Day 3, approximately 24 h after the second dose of study drug, the third dose of study drug was not administered, and a follow-up chest CT was performed on Day 3 before rescue therapy was initiated. Total number of hospitalization days from randomization to hospital discharge was assessed as well as mortality at 30 days. A complete description of the secondary efficacy endpoints is included in the study protocol included in the Supplement. Safety assessments included clinical bleeding and other adverse events (AE) with severity ratings based on National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Study medication LTI-01 is a recombinant, human scuPA that has been cloned into CHO cells. It is formulated as a lyophilized powder designed for reconstitution with approximately 2.15 mL of sterile water for injection. The formulation is packaged in a 10 mL USP Type 1 glass vial (13 mm neck) finished with a chlorobutyl rubber stopper and sealed with an aluminum overseal with a flip-off cap. The reconstituted product is a sterile, single-use solution containing approximately 400,000 U in a formulation of 20 mM sodium citrate, 50 mM sodium chloride and 15 mg/mL mannitol, pH 4.5. Placebo is 0.9% sodium chloride for injection (USP Normal Saline). LTI-01 is designed to be stored at -20 ± 5 °C prior to use. Vials were reconstituted with approximately 2.15 mL sterile water, then brought to 6 ml with saline in a single syringe for thoracostomy tube administration followed by administration of 24 ml saline (30 ml total instillate), after which the tube was clamped for 3 h., then reopened. Statistical analyses Point estimates and 95% confidence intervals (CI) of the Day 7 treatment failure rates were summarized for the LTI-01 dosing arms and placebo. Each LTI-01 dosing arm was compared to placebo using a two- sided test with significance level alpha of 0.05, to test the hypothesis of no difference in proportions for the primary endpoint for each of the LTI-01 dosing arms vs. placebo. Of note, the modified intention-to-treat population (n = 40) that included patients who received at least one dose of study drug was used for efficacy analyses. No adjustment for multiplicity was performed. Analyses of pleural opacification, indicative of pleural drainage, employed a two-sample t-test to test the hypothesis that the absolute change in pleural opacity in an LTI-01 group was not significantly different from that of placebo at an alpha of 0.05. The test was performed for each of the 4 groups. Additional tests were performed using one-way analysis of variance (ANOVA) to test that the absolute change in pleural opacity in an LTI-01 group is not different from that of placebo. To avoid any violations of normality assumptions, the data transformations were examined prior to analysis. The assumed response in the active dosing arms relative to placebo ranged from 15% to 25% in all considered models. Based on assumptions from the literature [5, 10, 11] and the Phase 1 study [8], a planned sample size of 25 to 40 patients per dosing arm was projected to provide 85% to 96% power for rejecting the null hypothesis of no difference in the primary endpoint between an LTI-01 dosing arm and placebo arm with an effect size ranging from 0.48 to 0.60 using a two-sided t-test with significance level alpha of 0.05. The same sample sizes were projected to support the identification of an effective dose(s) via MCP-Mod approach, with 90% power and 2.5% 1-sided significance level. Results Patients Enrolment was limited to a total of 43 patients of a group of 145 pre-screened and of whom 40 were dosed in one of 4 groups: 400,000 U, 800,000 U, 1,200,000 U, and placebo, as shown in Fig. 1A. The target enrolment in this study of 100–160 subjects (Fig. 1A) was not achieved due in large part to research restrictions related to the COVID-19 pandemic. In total, 43 patients were enrolled across 19 participating hospitals, corresponding to an average enrollment of approximately 2.3 patients per site. Importantly, enrollment was not evenly distributed with some sites enrolling as many as four patients (Supplement, Additional Tables and Figures, Fig. 1). Subjects with infected non-draining pleural effusions received intrapleural administration by chest tube of study drug or placebo once daily for up to 3 days (please see Supplement, study protocol for details). Demographics of the study subjects are shown in Table 1. The primary analysis in Study LTI-01-2001 was conducted once all 40 enrolled subjects had completed their Day 30 assessments. Recruitment was put on hold, and safety was reviewed by the independent Data Monitoring Committee (iDMC) after 3 subjects had been entered into each dosing arm (12 subjects total) given that the 1,200,000 LTI-01 dose had not be studied previously. The iDMC determined that no tolerability issues had occurred. Dosing then proceeded in the four-dose groups as described In the Patient’s section above. Primary outcome: protocol defined treatment failure There was no significant difference in incidence of treatment failure within 7 days of initiation of treatment between LTI-01 and placebo groups using the protocol definition of treatment failure (Table 2). When all patients treated with any dose of LTI-01 were considered, 11/29; 37.9% of patients experienced protocol-defined treatment failure while a comparable 4/11; 36% of placebo-treated patient had treatment failure. There were no deaths in any patients through 7 days of follow-up. Table 2Primary Efficacy Analysis: Incidence of Treatment Failure (Protocol Definition) Within 7 Days of TreatmentTreatment FailureLTI-01 (400,000 U)N = 10LTI-01 (800,000 U)N = 9LTI-01(1,200,000 U)N = 10All LTI-01N = 29PlaceboN = 11Yes, n (%)3 (30%)3 (33.3%)5 (50%)11 (37.9%)4 (36%)No, n (%)7 (70%)6 (66.7%)5 (50%)18 (62.1%)7 (63%)Odds Ratio (OR)0.770.911.571.0495% CI(0.12, 4.84)(0.14, 5.83)(0.26, 9.51)(0.24, 4.44)P-value0.7820.9170.6250.958Legend. CI Confidence interval Primary Efficacy Analysis: Incidence of Treatment Failure (Protocol Definition) Within 7 Days of Treatment Legend. CI Confidence interval The protocol defined treatment failure as requiring alternative pleural therapy and meeting protocol-specified criteria for surgical referral irrespective of subsequent treatment. These criteria included at least 2 signs of ongoing systemic inflammatory response syndrome (SIRS) or pleural sepsis and inadequate pleural fluid drainage. Examples of limitations concerning the protocol checklist are described in the Supplement. Pre-specified sensitivity analysis 1: independent endpoint assessment committee (iEAC) assessment of treatment failure The iEAC evaluated blinded patient profiles that included brief demographic information, concomitant medications, pleural fluid characteristics, graphical representations of the SIRS/pleural sepsis criteria and had access to the baseline and follow-up CT scan images. The iEAC did not have access to site identification information, chest tube drainage information, or chest CT pleural opacity volume assessments made by a central reader. Examples of limitations of iEAC assessment in case examples are described in the Supplement. Based on this analysis, the 400,000 U LTI-01 group approached statistical significance versus placebo controls (1 treatment failure/10 subjects, OR 0.09, CI 0.01–1.02, P = 0.052), while no other LTI-01 group demonstrated better outcomes by 7 days after initiation of LTI-01. Pre-specified sensitivity analysis 2: treatment failure defined as requiring rescue therapy as determined by the treating physician In the second prespecified endpoint analysis, treatment failure was defined as needed for rescue therapy (other IET or surgery) as determined by the treating physician at 7 days, the 400,000 U and 800,000 U LTI-01 dose groups showed nonsignificant trends towards improved outcomes. The placebo incidence of treatment failure was 72.7%. That of the 400,000 U group was 40% (OR 0.26, 95% CI, 0.04–1.61, P = 0.147). The 800,000 U incidence was 44.4% (OR 0.31, 95%, CI 0.05–2.02, p = 0.221). A Forrest Plot of the primary outcome analyses of LTI-01 dosing groups versus placebo are illustrated in Fig. 2. A side-by-side comparison of the numbers of patients with treatment success or failure as defined by protocol, iEAC assessment, and physician-assessed rescue therapy sensitivity analysis is shown in Table 3. Forest Plot of Odds Ratio Using Different Treatment Failure Definitions. Legend. N=number of patients in the LTI-01 groups Table 3Side by Side Comparison of Numbers of Patients with Treatment Failure or Success Across All Treatment Arms as Defined by Protocol, iEAC or Physician-assessed Rescue (Investigator) Therapy DefinitionsTreatment failure responseLTI-01400,000 UN = 10LTI-01800,000 UN = 9LTI-011,200,000 UN = 10PlaceboN = 11Protocol definition Yes, n %)3 (30.0)3 (33.3)5 (50.0)4 (36.4) No, n (%)7 (70.0)6 (66.7)5 (50.0)7 (63.6)iEAC definition Yes, n (%)1 (10.0)6 (66.7)5 (50.0)6 (54.5) No, n (%)9 (90.0)3 (33.3)5 (50.0)5 (45.5)Investigator definition Yes, n (%}4 (40.0)4 (44.4)6 (60.0)8 (72.7) No, n (%)6 (60.0)5 (55.6)4 (40.0)3 (27.3) Side by Side Comparison of Numbers of Patients with Treatment Failure or Success Across All Treatment Arms as Defined by Protocol, iEAC or Physician-assessed Rescue (Investigator) Therapy Definitions Incidence of surgery at day 30 Data collected for the endpoint captured actual surgery rather than referral for surgery (Table 4) through Day 30. The incidence of surgery at Day 30 rate was highest for placebo (45.5%) compared to the LTI-01 treated groups; LTI-01 400,000 U group: 30.0%, LTI-01 800,000 U group: 22.2%, LTI-01 1,200,000 U group: 10.0%, and LTI-01 group composite: 20.7%). Chi square = 0.12 all LTI-01 groups combined versus placebo. Table 4Secondary Efficacy Analysis: Logistic Regression of Incidence of Surgery at Day 30ResponseLTI-01 (400,000 U)N = 10LTI-01 (800,000 U)N = 9LTI-01 (1,200,000 U)N = 10All LTI-01N = 29PlaceboN = 11Incidence of Referral to Surgery at Day 30, n (%)3 (30.0)2 (22.2)1 (10.0)6 (20.7)5 (45.5)Odds Ratio0.510.340.140.3295% CI(0.08, 3.08)(0.05, 2.43)(0.01, 1.59)(0.07, 1.41)p-value0.4590.2800.1130.131Legend. Abbreviations: CI Confidence interval, n Number of patients with non-missing data within the specific category, N Number of patients; Population, RAPID composite clinical mortality risk score consisting of renal, age, purulence, infection source, and dietary factorsPercentages were based on NThe logistic regression was performed with referral to surgery as the response variable, dose group, along with the RAPID score at randomization as the covariate Secondary Efficacy Analysis: Logistic Regression of Incidence of Surgery at Day 30 Legend. Abbreviations: CI Confidence interval, n Number of patients with non-missing data within the specific category, N Number of patients; Population, RAPID composite clinical mortality risk score consisting of renal, age, purulence, infection source, and dietary factors Percentages were based on N The logistic regression was performed with referral to surgery as the response variable, dose group, along with the RAPID score at randomization as the covariate Changes in pleural opacification Change from baseline in pleural opacity volume at Day 4 was the key secondary efficacy endpoint since drainage of infected pleural fluid is a key element in controlling the source of the infection along with the administration of appropriate antibiotic therapy. The change in pleural opacity volume was assessed by chest CT by measuring the volumetric size (absolute size in liters) and relative percentage change in opacification of the infected pleural effusion at baseline and after treatment with study drug, indicating how much pleural fluid drained. Figure 2 shows that most subjects in all LTI-01 groups had a relative decrease from baseline in pleural opacity with a trend toward maximally decreased opacification in the 800,000 LTI-01 group. The outlier in the 800,000 U dose group had a 123% increase in pleural opacity volume presented with an esophageal perforation and pleural fluid characteristics suggesting leakage of swallowed oral secretions into the pleural space. For statistical comparisons, a ranked based ANCOVA was used as pre-specified in the trial statistical analysis plan since the normality assumption was not met. The 400,000 U and 800,000 U and overall LTI-01 dose groups showed a significant difference from placebo in absolute change of pleural opacity volume (p < 0.05) and similar trend with relative change from baseline pleural opacity volume (p-values 0.082 and 0.064, respectively), shown in Table 5. Relationship of changes in pleural opacification and clinical outcomes Tables 1 and 2, Supplement, Additional Tables section) illustrate that the relative change from baseline in pleural opacity volume can be divided into quartiles with Quartile 1 being the 25% of ubjects with the largest decrease and Quartile 4 represents the 25% with the smallest decrease. There was a significant correlation between treatment failure and pleural opacity volume change (p-values < 0.05), i.e. higher incidence of treatment failure is associated with smaller pleural opacity volume reduction (Supplement, Additional Table 2). Based on these considerations, Quartile 4 subjects with the smallest relative decrease in pleural opacity volume had a 90% treatment failure rate in contrast to Quartile 1 subjects with the largest relative decrease in pleural opacity volume who had a 20% treatment failure rate. Based on this analysis, pleural opacity volume was indicative of the need for rescue therapy. Pleural fluid drainage An exploratory endpoint in this trial was to assess the daily amount of fluid draining out of the chest tube. The mean cumulative fluid drainage was greater in the LTI-01 groups when at 1, 2 and 3d after initiation of LTI-01 IET compared to the placebo-treated patients but these trends did not achieve significance versus placebo (Table 3, Supplement, Additional Tables section). Safety analyses Based on the analysis of treatment emergent adverse events (TEAEs) in the LTI-01 groups, there were no safety signals of concern (Table 6) and specifically no episodes of intrapleural or systemic bleeding events assessed as related to study drug (Table 4, Supplement, Additional Tables section). Of note, there were no serious TEAEs related to study drug in any of the treatment groups. In the LTI-01 groups, 77.8% of TEAEs were unrelated to the agent. The most frequently occurring TEAEs (treatment emergent adverse events) were chest pain (4 subjects), constipation (4 subjects), and diarrhea (4 subjects) followed by insomnia (3 subjects). Five subjects died during the follow-up period up to 6 months after active dosing. All deaths occurred in LTI-01 treatment groups and none in the placebo group. These deaths occurred in patients with substantial baseline comorbidities and advanced underlying disease processes, and all events were assessed by investigators as unrelated to study drug. Importantly, the deaths reflected heterogeneous clinical causes rather than a common causal pattern (Supplement, Subject Mortality Section). No death was attributed to LTI-01 treatment. Additional details about each of these patients and of patients experiencing TEAEs is included in the Supplement. Table 6Summary of Treatment Emergent Adverse Events (TEAE)s)CategoryLTI-01(400,000 U)N = 10n (%)LTI-01(800,000 U)N = 9n (%)LTI-01 (1,200,000 U)N = 10n (%)LTI-01OverallN = 29n (%)PlaceboN = 11n (%)OverallN = 40n (%)Number of Subjects with TEAE5 (50.0)7 (77.8)6 (60.0)18 (62.1)8 (72.7)26 (65.0)Number of Subjects with Serious TEAE1 (20.0)01 (16.7)2 (11.1)1 (12.5)3 (11.5)Number of Subjects with Treatment Related TEAE1 (20.0)2 (28.6)1 (16.7)4 (22.2)04 (15.4)Number of Subjects with Serious Treatment Related TEAE000000Number of Subjects with TEAE Leading to Study Drug Discontinuation1 (20.0)01 (16.7)2 (11.1)02 (7.7)Severity/CTCAE Grade Grade 1 (Mild)2 (40.0)3 (42.9)2 (33.3)7 (38.9)7 (87.5)14 (53.8) Grade 2(Moderate)03 (42.9)03 (16.7)03 (11.5) Grade 3 (Severe)2 (40.0)1 (14.3)3 (50.0)6 (33.3)1 (12.5)7 (26.9) Grade 4(Life threatening)000000 Grade 5 (Death)1 (20.0)01 (16.7)2 (11.1)02 (7.7)Relationship to Study Drug Related1 (20.0)2 (28.6)1 (16.7)4 (22.2)04 (15.4) Not Related4 (80.0)5 (71.4)5 (83.3)14 (77.8)8 (100)22 (84.6)Legend. TEAE Treatment-emergent adverse event, National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) Summary of Treatment Emergent Adverse Events (TEAE)s) Grade 2 (Moderate) Grade 4 (Life threatening) Legend. TEAE Treatment-emergent adverse event, National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) Discussion This was, to our knowledge, the first-ever dose-ranging, randomized, double-blind, placebo-controlled, efficacy trial of a form of IET; LTI-01. The trial was performed at 18 US institutions in hospitalized subjects with infected, non-draining pleural effusions. The study was completed with last patient, last visit (Day 180) in July 2022. The intended enrollment was 25–40 subjects per arm (100–160 total with 3 LTI-01 doses and placebo). Enrollment was limited to 43 subjects due in large part to the COVID-19 pandemic, of which 40 subjects were dosed and included in the safety and efficacy analysis. While the use of a placebo group and study design may have contributed to this problem, we believe that resources and manpower allocations for the care of large numbers of COVID-19 patients were mainly responsible for limited enrollment. The analysis and interpretation of this study are thus constrained by relative paucity of enrollment and available data, which are major limitations of this trial. There were no significant differences between any LTI-01 group and placebo-treated patients in the incidence treatment failure or death within 7 days using the protocol definitions (Protocol Supplement). However, important findings including significant and nonsignificant efficacy signals of LTI-01 compared with placebo were found when considering the totality of the data. These exploratory findings also bear implications for the design of a future Phase 2b study in which better efficacy assessments can derive from larger treatment cohorts. The protocol defined failure as requiring alternative pleural therapy and meeting protocol-specified criteria for surgical referral irrespective of actual subsequent treatment. The criteria included at least 2 signs of ongoing systemic inflammatory response syndrome (SIRS) or pleural sepsis and inadequate pleural fluid drainage, which to our knowledge have not been used previously as part of a drug development program targeting regulatory approval. Because these criteria had not been assessed previously, subjects requiring rescue therapy were considered treatment failures were discussed with the medical monitor and this outcome was managed accordingly in the statistical analyses. It is possible that the alternative treatments could have affected long-term safety or efficacy outcomes assessed at 30 days after LTI-01 treatment. Prespecified sensitivity analyses were performed, one by the iEAC and the other based on the treating physician’s assessment that alternative treatment (either other IET or surgery) was required. The iEAC assessment concluded that the 400,000 U LTI-01 dose resulted in less treatment failure than the placebo group, while the rescue treatment sensitivity analysis revealed nonsignificant trends towards reduced treatment failure in the 400,000 or 800,000 LTI-01 versus placebo groups (Please see outcome sensitivity analysis sections, Results). These findings are promising but require confirmation and thereby support further testing in a larger phase 2b trial. The discordance between protocol checklist outcomes and iEAC sensitivity analysis outcomes (Fig. 2; Table 3) triggered a reexamination of The Phase 2 protocol checklist criteria for defining treatment failure, which were found to have limitations. Situations in which subjects required surgery for evolving pleural fibrosis or trapped lung were not well captured by the protocol definition and in two placebo and one LTI-01 1,200,000 U dose patients, rescue surgeries were performed at the discretion of the providers in the two placebo-treated patients despite meeting criteria as protocol treatment successes. If these two placebo controls were assessed as treatment failures, the low treatment failure rate in this group would have been increased towards expected levels. Given that protocol design under which this study was conducted, the statistical analyses were properly applied, but it is clear that protocol adjustments to include such patients as treatment failures should be incorporated into the design of a follow up phase 2b trial. These cases were, however, designated as treatment failures by iEAC and rescue therapy sensitivity analyses, accounting for some of the disparate conclusions. The iEAC assessments also had incomplete clinical information that appeared to have resulted in different conclusions, one in the 400,000 U and another in a patient in the 800,000 U LTI-01 group, which further contributed to the disparities. The sensitivity analyses are intriguing, clinically germane and supportive of clinical efficacy but do not obviate the protocol defined outcomes showing no difference in treatment failure. In a related outcome assessment, there was a decrement in the incidence in actual surgeries in the LTI-01 treatment versus placebo groups. Although the trends did not achieve statistical significance, more surgeries were done in the placebo versus LTI-01 groups. In the aggregate, we infer that analyses of treatment groups with larger numbers are required to reach conclusions about the efficacy of LTI-01 for non-draining empyema/CPE. In addition, protocol adjustments that better square the requirement for surgery of trapped lung or rescue IET will need to be incorporated into the study design of future trials. As we plan the phase 2b trial, we will consider the possibility that the present study protocol was overly stringent. While we are uncertain if variation as to how the checklist was applied at site level, or the inherent heterogeneity of the empyema population were confounders, we do not now anticipate using SIRS definitions in the same manner as reported here, may focus on pleural opacification as the primary outcome and compare the ability of LTI-01 to standard of care with currently used IET (tPA/DNase) rather than placebo to clear nondraining pleural fluid in patients with empyema/CPE. Changes in pleural opacification are important indicators of the efficacy of pleural drainage and there is clear evidence that they relate to the ability of IET to improve clinical outcomes. The findings of the MIST2 and MIST3 trials in particular strongly suggest that reduction of pleural opacification relates to clinically important outcome such as referral to surgery or length of hospital stay or quality of life [5, 12]. In this trial, the absolute reduction in pleural opacification determined by noncontract chest CT imaging achieved statistical significance for both the 400,000U and 800,000U LTI-01 treated patients versus placebo (Table 5). The reduction of relative pleural opacification versus baseline approached statistical significance for the same groups, with the greatest relief or opacification observed in the 800,000 U treated patients (Table 5; Fig. 3). There was no difference in pleural opacification in the 1,200,000 U LTI-01 group versus placebo. Differences in disease severity, suggested by the highest RAPID scores in this group or differences in aberrant intrapleural fibrin turnover or profibrogenic mediator expression may have been contributory. Along these lines, we also plan to soon test whether the individual responses of the fibrinolytic system in the pleural fluids of patients treated with LTI-01 or placebo versus baseline levels and infer that derangements relate to outcomes in the 1,200,000 U LTI-01 and all groups [8]. It is conceivable that all these factors could have influenced opacification readouts at the 1.200,000U dose of LTI-01 but this dose appears to have little predicate for future clinical trial testing. Based on the findings, a 400,000 or 800,000U dose of intrapleural LTI-01 may be considered for future clinical trial testing. Relative Change in Pleural Opacity Volume by Dose Group. Legend. Red line represents the median value. POVOL: pleural opacity volume While relative pleural opacification was extrapolated from chest X-rays in MIST2 and directly measured by chest CT in this study, the magnitude of change was greater in the LTI-01 800,000 group (-55.8%) versus placebo (-16.1%) (than that previously reported in MIST2 (tPA/DNase − 29.5, placebo − 17.2%). Caveats include measurement of medians of relative opacification in this trial versus means+/- standard deviations in MIST2, much larger patient groups of about 50 patients/group, 200 total in MIST2 and measurement of pleural opacification at day 7 in MIST2 [5] versus at day 4 in the present study. However, we believe that the data supports further evaluation of the effects of LTI-01 on pleural opacification in a future phase 2b trial. Pleural fluid evacuation increases after administration of tPA/DNase-based IET and occurs in conjunction with reduction of sequestered intrapleural fluid collections [5, 13]. The same trends in thoracostomy tube drainage and relative pleural opacification were found by either CXR or CT imaging in a limited number of patients (n = 14) who received LTI-01 50,000-800,000 U LTI-01 daily over 3 days in our preceding phase 1 trial [8]. Trends of increased chest tube drainage were similarly observed in this study at each dose of intrapleural LTI-01 (Supplement Additional Table 3) and we speculate that the relatively low numbers of patients evaluated contributed to the lack of statistically significant increments. Surprisingly, cumulative thoracostomy drainage was not increased in the 1.2 million U LTI-01 treatment group, consistent with the inability of this dose to approach significant improvement of absolute or relative pleural opacification. The relationship between reduced pleural opacification and other clinical outcomes in IET trials remains a point of interest. While we acknowledge that changes in pleural opacification are a surrogate outcome, there is evidence now that other clinical outcomes including hospital length of stay, referral or performance of surgery and extended mortality; 30 or more days beyond IET are related to improvement in pleural opacification [5, 12]. We stratified the levels of pleural opacification by quartiles (Supplement Additional Table 1) after which we determined that the severity of opacification was significantly related to treatment failure (Supplement Additional Table 2). While the analysis is still limited by the relatively low numbers of patient responses evaluated (N = 40), it lends further support for the concept that changes in pleural opacification by IET relate to clinically meaningful outcomes. The safety assessments consolidate the favorable adverse event profile that we observed in the phase 1 LTI-01 dose ranging study [8]. Importantly, no bleeding events were again observed, attesting to the safety of administration of intrapleural LTI-01, including the highest 1,200,000U dose that exceeded this tested in phase 1. It is possible that the intrapleural processing of the proenzyme scuPA may offer advantages versus delivery of an active serine protease such as tPA [1, 14]. While pleural fluid analyses can offer insight into individual responses to treatment [8], group trends could be obviated by the low numbers available in this study. It would be anticipated that plasminogen activator inhibitor-1; PAI-1, (the major inhibitor of pleural fluid plasminogen activator activity) levels and activity are most elevated in patients prone to treatment failure, as PAI-1 increases intrapleural septation, decreases pleural drainage and extends length of stay and mortality assessed over 30 days [1, 15]. Single chain uPA generated by LTI-01 as a part of its intrapleural processing, it could induce mesothelial cell TGF-β and Tissue Factor (TF) expression [1]. Increased intrapleural TGF-β promotes intrapleural organization and fibrosis [16], as does TF [1, 17]. Dedicated biochemical studies are comprehensive, labor intensive and outside the scope of this report, but we plan to conduct such analyses on pleural fluids from patients in this trial and share the findings in the future. Conclusions This trial offers several considerations that can potentially advance the field. This is the only dose-ranging phase 2 study of a form of IET of which we are aware and the first efficacy trial in which efficacy of LTI-01 was tested. This trial design enables the discovery of counter-intuitive responses to IET, as we observed with lack of reduction of pleural opacification in patients treated with 1,200,000 U LTI-01. Dosing of IET agents can be refined in a data-driven manner using this format, which addresses some of the empiricism that surrounds the current use of IET [4]. The favorable safety profile of LTI-01 IET originally identified in phase 1 testing was sustained in this trial and may offer advantages over tPA/DNase bleeding rates of about 4% [18]. The favorable reductions of pleural opacification and evidence of its relationship to reduced treatment failure support further evaluation of LTI-01 IET in a properly powered phase 2b study, which is feasible and now being planned. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Acknowledgements Not applicable. Abbreviations 01-recombinant single chain urokinase plasminogen activator Intrapleural enzymatic therapy 1-plasminogen activator inhibitor 1 β-transforming growth beta 1 Tissue factor Treatment-emergent adverse event National Cancer Institute’s Common Terminology Criteria for Adverse Events Authors’ contributions CRL, JA, AM, SS, AC, JK, PJ, MS, DA, MW, SA. M A-H, KM, JP, LY, FK, FM and GC recruited patients, obtained informed consent, managed trial patients and assisted with the writing and review of the manuscript. BW helped develop the study and oversaw the sponsor’s financial and logistic commitments to the trial. NMR consulted on trial design, protocol development, review of the data and writing of the manuscript. CA and KPS performed statistical analyses and reviewed the manuscript. SS organized the trial design, protocol, trial data archive, reviewed the data related to the trial and contributed to writing of the manuscript. SI contributed to the trial design and trial data and its interpretation and wrote the manuscript. Funding Lung Therapeutics, Inc. Word count: 331. Data availability All resource data generated or analyzed during this study are included in the supplementary data in an Excel file format. The trial protocol, supplemental patient data and individual author competing interest attestations are also available in the supplement that accompanies this report. Declarations Ethics approval and consent to participate This study received Institutional Review Board approval from all participating institutions prior to study initiation. All subjects provided written informed consent prior to participation. This trial was conducted in accordance with ethical principles from the Declaration of Helsinki, and clinical research guidelines established by the United States Code of Federal Regulations (21 CFR Parts 50, 56, and 312) and the International Conference on Harmonisation (ICH) E6(R1) Guideline for Good Clinical Practice (GCP). Consent for publication Not applicable. Competing interests Competing interests. Dr. Idell founded Lung Therapeutics, Inc. (LTI), which was acquired by Aileron, Inc, now called Rein Therapeutics, Inc. He has an equity position in Rein and received compensation as Chief Scientific Officer for LTI until about 2021. He remains a consultant for LTI, paid through about 2021. His declared conflicts of interest are managed through the UTHSCT and the UT System. He is an inventor on a relevant patent (USPTO 7332469) held by the UT Board of Regents and licensed to LTI. Drs. Rahman and Sheomaker have received consultancy fees from Lung Therapeutics, Inc. Dr. Windsor is President and Chief Executive Officer at Rein Therapeutics Inc. rebranded from Aileron, Inc., which acquired LTI and LTI before that, and is a director (since 2013) who receives equity and financial compensation for his roles at the company. Dr. Kurman has received grants from Biodesix, CSA Medical, Galvanize, Medtronic, Nuvaira, PrognomiQ, Pulmonx, and Veracyte and has served as a consultant for Ambu, Biodesix, Circulogene, Cook, Galvanize, Intuitive, Medtronic, Merit, Noah Medical, Pinnacle Biologics, PrognomiQ, Pulmonx, Steris, Veracyte, and Verona Pharma. Dr. Musani has served as a consultant for Intuitive. He has received research grants from Galvanize, Pinnacle, Veracyte, and Biodesix and has shares in EON. ICJME conflict of interests forms are available for each author in the supplemental material. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Data Availability Statement All resource data generated or analyzed during this study are included in the supplementary data in an Excel file format. The trial protocol, supplemental patient data and individual author competing interest attestations are also available in the supplement that accompanies this report.